TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03021486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02231138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abelmoschus manihot (AM)
Description: Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
Study: NCT02979912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Lysate
Description: Eye drops of Platelet Lysate
Study: NCT03021486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04185012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab 30 mg administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
Study: NCT04519775

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
Study: NCT01969422

Intervention type: PROCEDURE
Intervention: observation
Description: intervention is the contact with online question answering serice ad subseudd
Study: NCT01887470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full dose preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full dose preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split dose preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split dose preparation
Study: NCT04196998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
Study: NCT01840553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral sodium phosphate tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Study: NCT01042028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus, Cetuximab, Irinotecan
Description: Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, Oxaliplatine
Description: Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
Study: NCT02998814

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acid-etch
Description: acid-etch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-etch adhesive
Description: Self etch (7th generation ) bonding agent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: etch-and-rinse adhesive
Description: Total etch bonding agent (5th generation)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-etch adhesive after acid-etch
Description: acid etch + self-etch adhesive Self etch (7th generation ) bonding agent
Study: NCT03744468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A425
Description: Humanized IgG1-variant monoclonal antibody against TIM-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A425
Description: Humanized IgG1-variant monoclonal antibody against TIM-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A425
Description: Humanized IgG1-variant monoclonal antibody against TIM-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Humanized, IgG4-variant monoclonal antibody against PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Humanized, IgG4-variant monoclonal antibody against PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Humanized, IgG4-variant monoclonal antibody against PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Human anti LAG-3 IgG4-kappa antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Human anti LAG-3 IgG4-kappa antibody
Study: NCT06452953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suanzaoren decoction
Description: The Suanzaoren decoction is a Chinese herbal formula known for nourishing the blood, calming the mind, and nourishing the heart and liver

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone 1 mg
Description: Eszopiclone is used in the treatment of various types of insomnia.
Study: NCT02856425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
Study: NCT00192699

Intervention type: DEVICE
Intervention: Bimetric femoral stem
Description: Cemented Bi-Metric femoral stem
Study: NCT02427607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
Study: NCT02729688

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: customized pressure guide bandage
Description: Investigators developed the customized pressure guide elastic bandage (CPG-EB). The experienced nurse applied the elastic bandages to each patient with sub bandage pressure monitoring. The target pressure was 35-45 mmHg. Measurements of the pressure applied by bandages was performed at point B1 corresponding to the height where the Achilles' tendon turns into the gastrocnemius muscle with Picopress (MicroLAB Elettronica, Ponte S. Nicolo, Italy). If the target pressure 35-45 mmHg was achieved, the circular ink stamp was applied into the entire bandages. The markers in CPG-EB had elliptical shape when they were not stretched. They turned into circular shape when they were stretched.~For the OEB, Bandaging was applied by spiral methods. Three EB were applied with 50 % stretching and 50% overlapping from foot to just below knee level.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary elastic bandage
Description: Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
Study: NCT00819728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 35mg/m2 IV each week for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2 IV each week for 4 weeks
Study: NCT05377957

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: Collection of patient-reported outcomes concerning general and health-related quality of life and impact of uveal melanoma diagnosis

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: Collection of patient-reported outcomes concerning general and health-related quality of life and impact of uveal melanoma diagnosis

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: Collection of patient-reported outcomes concerning general and health-related quality of life and impact of uveal melanoma diagnosis

Intervention type: OTHER
Intervention: Discrete choice experiment
Description: Assessment of patient preferences for outcomes of proton therapy and enucleation

Intervention type: OTHER
Intervention: Discrete choice experiment
Description: Assessment of patient preferences for outcomes of proton therapy and enucleation

Intervention type: OTHER
Intervention: Shared decision-making analysis
Description: Assessment of shared decision-making from the perspective of the patient (by questionnaire), physician (by questionnaire) and a neutral observer (by audiotape), combined with patient-reported satisfaction and regret of the treatment decision (by questionnaire)

Intervention type: OTHER
Intervention: Shared decision-making analysis
Description: Assessment of shared decision-making from the perspective of the patient (by questionnaire), physician (by questionnaire) and a neutral observer (by audiotape), combined with patient-reported satisfaction and regret of the treatment decision (by questionnaire)

Intervention type: OTHER
Intervention: Impact of side-effects analysis
Description: Assessment of the impact of side-effects by questionnaire

Intervention type: OTHER
Intervention: Impact of side-effects analysis
Description: Assessment of the impact of side-effects by questionnaire
Study: NCT02910700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT04755881

Intervention type: OTHER
Intervention: Occurence of biphasic reaction following anaphylaxis
Description: Prospective observation for biphasic reaction following anaphylaxis and subsequent analysis (comparison between usual care and the care that would have been suggested by the three proposed clinical decision rules).
Study: NCT03987438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with APP
Description: The lifestyle intervention will be launched by an APP installed in participants' private mobile phones, including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management. Nutrition recommendation is conducted according to the Chinese Dietary Guide, Chinese and International Guidelines of Gestation Diabetes Management. Exercise guidance is given based on the Guidelines for National Fitness of China, Chinese and International Guidelines of Gestation Diabetes Management. Psychological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP. The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together to modify the behavioral supports individually based on the feedback of their characteristics and performance recorded in the APP.
Study: NCT02292238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benfotiamine
Description: * To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~* To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benfotiamine
Description: * To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~* To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate.
Study: NCT01789320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide (Triesence®)
Description: 4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
Study: NCT02856425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
Study: NCT03706638

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous Sulfate
Description: Patients would be randomized to either taking ferrous sulfate daily or every other day (on non consecutive days).

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous Sulfate
Description: Patients would be randomized to either taking ferrous sulfate daily or every other day (on non consecutive days).
Study: NCT03830528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 Low Dose
Description: KW-6356 will be administered as single doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 Middle Dose
Description: KW-6356 will be administered as single doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 High Dose
Description: KW-6356 will be administered as single doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 X Dose
Description: KW-6356 will be administered as multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 Y Dose
Description: KW-6356 will be administered for Japanese healthy men as multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 Y Dose
Description: KW-6356 will be administered for Japanese healthy men as multiple doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All study cohorts (except Part C) are placebo controlled.
Study: NCT06666920

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: laser irradiation
Description: Immediately after applying the bleaching agent, the gel on the left upper and lower hemiarches (teeth 21-25 and 31-35) was irradiated using an Er,Cr:YSGG laser (2780 nm). Specifically, an Er,Cr:YSGG solid-state laser device (Waterlase MD Turbo, BIOLASE, Irvine, CA, USA) equipped with a Z-type glass tip (MZ8) measuring 800 μm in diameter and 6 mm in length was used. This tip was attached to the laser system's gold handpiece. The laser parameters for the treatment included an average output power of 1.25 W, a pulse duration of 700 μs (S-mode), and a pulse repetition rate of 10 Hz, without water or air flow, according to a previous study. Each tooth received two 15-s irradiation intervals, one for each 20-min session (totaling 30 s), while maintaining the laser handpiece approximately 2.5 cm from the tooth surface, perpendicular to the enamel. The gel was irradiated using a scanning mode, with the handpiece moved slowly in both horizontal and vertical directions at a speed of 2 mm/s.
Study: NCT06666816

Intervention type: OTHER
Intervention: inapplicable
Description: inapplicable
Study: NCT02856425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
Study: NCT02381730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Description: Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)
Study: NCT02856425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
Study: NCT03361995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Procedure using the ZOLL Thermogard XP3 IVTM System
Description: Cooling Procedure with ZOLL Thermogard XP3 IVTM System before and after Percutaneous Coronary Intervention (PCI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Standard of Care for PCI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Standard of Care for PCI
Study: NCT04622670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Receive DVD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Media Intervention
Description: Receive DVD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02463344

Intervention type: BIOLOGICAL
Intervention: MA09-hRPE
Description: Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells